Gilead Sciences
Market Cap
US$75.9b
Last Updated
2020/10/20 00:17 UTC
Data Sources
Company Financials +
Executive Summary
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential and slightly overvalued.
Similar Companies
Share Price & News
How has Gilead Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GILD's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-6.1%
GILD
-3.4%
US Biotechs
-2.4%
US Market
1 Year Return
-8.0%
GILD
35.9%
US Biotechs
18.2%
US Market
Return vs Industry: GILD underperformed the US Biotechs industry which returned 39.3% over the past year.
Return vs Market: GILD underperformed the US Market which returned 19.5% over the past year.
Shareholder returns
| GILD | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.1% | -3.4% | -2.4% |
| 30 Day | -6.9% | 0.7% | 4.2% |
| 90 Day | -20.6% | -4.7% | 6.3% |
| 1 Year | -4.5%-8.0% | 38.3%35.9% | 20.9%18.2% |
| 3 Year | -16.1%-24.4% | 18.5%12.5% | 41.2%31.8% |
| 5 Year | -36.4%-45.4% | 17.2%8.9% | 84.8%63.9% |
Price Volatility Vs. Market
How volatile is Gilead Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Do Institutions Own Gilead Sciences, Inc. (NASDAQ:GILD) Shares?3 weeks ago | Simply Wall St
Reflecting on Gilead Sciences' (NASDAQ:GILD) Share Price Returns Over The Last Five Years1 month ago | Simply Wall St
Here's Why We're Wary Of Buying Gilead Sciences' (NASDAQ:GILD) For Its Upcoming DividendValuation
Is Gilead Sciences undervalued compared to its fair value and its price relative to the market?
40.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GILD ($60.57) is trading below our estimate of fair value ($101.5)
Significantly Below Fair Value: GILD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GILD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GILD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GILD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GILD is overvalued based on its PB Ratio (4.2x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Gilead Sciences forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
23.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GILD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: GILD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GILD's is expected to become profitable in the next 3 years.
Revenue vs Market: GILD's revenue (1.1% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: GILD's revenue (1.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GILD's Return on Equity is forecast to be high in 3 years time (26.3%)
Next Steps
Past Performance
How has Gilead Sciences performed over the past 5 years?
-38.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GILD is currently unprofitable.
Growing Profit Margin: GILD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GILD is unprofitable, and losses have increased over the past 5 years at a rate of 38% per year.
Accelerating Growth: Unable to compare GILD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GILD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: GILD has a negative Return on Equity (-1.58%), as it is currently unprofitable.
Next Steps
Financial Health
How is Gilead Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($24.6B) exceed its short term liabilities ($10.6B).
Long Term Liabilities: GILD's short term assets ($24.6B) do not cover its long term liabilities ($27.2B).
Debt to Equity History and Analysis
Debt Level: GILD's debt to equity ratio (128.9%) is considered high.
Reducing Debt: GILD's debt to equity ratio has increased from 74.9% to 128.9% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (39.5%).
Interest Coverage: GILD is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Gilead Sciences's current dividend yield, its reliability and sustainability?
4.49%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GILD's dividend (4.49%) is higher than the bottom 25% of dividend payers in the US market (1.62%).
High Dividend: GILD's dividend (4.49%) is low compared to the top 25% of dividend payers in the US market (4.66%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, GILD has been paying a dividend for less than 10 years.
Growing Dividend: GILD's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: GILD is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: GILD's dividends in 3 years are forecast to be well covered by earnings (45% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average management tenure
CEO
Dan O'Day (56 yo)
1.58yrs
Tenure
US$29,361,392
Compensation
Mr. Daniel P. O'Day, also known as Dan, serves as Member of Supervisory Board at Galapagos NV since April 28, 2020. He served as Non-Independent Director at Galapagos NV since October 22, 2019 until April ...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD29.36M) is above average for companies of similar size in the US market ($USD11.20M).
Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 1.58yrs | US$29.36m | 0.0038% $ 2.9m | |
| Executive VP & CFO | 0.92yr | US$9.62m | 0.0012% $ 888.5k | |
| Executive VP of Corporate Affairs | 5.25yrs | US$5.03m | 0.0012% $ 888.5k | |
| Chief Commercial Officer | 1.25yrs | US$8.05m | 0.00031% $ 235.4k | |
| Chief Medical Officer | 0.92yr | US$3.12m | no data | |
| Senior VP | 4.67yrs | no data | 0.0011% $ 812.5k | |
| Executive Vice President of Human Resources | 1.17yrs | no data | no data | |
| Executive Vice President of Research | 19.92yrs | US$569.78k | no data | |
| Executive Vice President of Pharmaceutical Development & Manufacturing | 15.25yrs | no data | no data | |
| Senior Vice President of HIV & Emerging Viral Infections | 2.17yrs | no data | no data | |
| Senior Vice President of Clinical Research | no data | no data | no data | |
| Senior Vice President of Research Biology | 0.67yr | no data | no data |
1.6yrs
Average Tenure
56.5yo
Average Age
Experienced Management: GILD's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 1.58yrs | US$29.36m | 0.0038% $ 2.9m | |
| Independent Director | 10.75yrs | US$449.98k | 0.0080% $ 6.1m | |
| Member of Scientific Advisory Board | no data | US$16.00k | no data | |
| Independent Director | 2.67yrs | US$394.98k | 0.0011% $ 835.3k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director & Member of Independent Health Policy Advisory Board | no data | US$429.98k | 0.0025% $ 1.9m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Lead Independent Director | 0.42yr | US$414.98k | 0.0071% $ 5.4m | |
| Independent Director | 4.17yrs | US$414.98k | 0.00011% $ 83.5k | |
| Chairperson of Scientific Advisory Board | no data | no data | no data |
2.7yrs
Average Tenure
70yo
Average Age
Experienced Board: GILD's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Gilead Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Gilead Sciences, Inc.
- Ticker: GILD
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$75.938b
- Shares outstanding: 1.25b
- Website: https://www.gilead.com
Number of Employees
Location
- Gilead Sciences, Inc.
- 333 Lakeside Drive
- Foster City
- California
- 94404
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GILD | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jan 1992 |
| GIS | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1992 |
| GILD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1992 |
| GIS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1992 |
| GILD | SNSE (Santiago Stock Exchange) | Yes | Common Stock | CL | USD | Jan 1992 |
| GILD | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1992 |
| 0QYQ | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1992 |
| GILD | BIT (Borsa Italiana) | Yes | Common Stock | IT | EUR | Jan 1992 |
| GILD | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1992 |
| GILD34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 2 REP 1 COM | BR | BRL | Apr 2016 | |
| GILD | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH 4 REP 1 COM USD0.001 | AR | ARS | Apr 2019 |
Biography
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. T ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/20 00:17 |
| End of Day Share Price | 2020/10/19 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.